Scientific advice
Prevention and control of communicable diseases in prison settings.
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
Technical Update
HIV Treatment
July 2017
Key populations brief
Accessed 2017
Key Populations Brief
Accessed November 2017
Tackling Tuberculosis in Under-Served Populations: A Resource for TB Control Boards and their partners
Key populations brief
Accessed November 2017
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Guidelines
June 2017
HIV strategic information for impact
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more